Estudio diseñado para evaluar la no inferioridad de crovalimab comparado con eculizumab en participantes con HPN que no han recibido previamente terapia con inhibidores del complemento.

Elegibilidad

Edad mínima: 2 YearsSexo: ALL

Criterios de inclusión

Body weight ≥ 40 kg at screening (pediatric participants with body weight \< 40 kg)
Willingness and ability to comply with all study visits and procedures
Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry
LDH level ≥ 2x ULN at screening (as per local assessment)
Vaccination against Neisseria meningitidis serotypes A, C, W, and Y\< 3 years prior to initiation of study treatment; or, if not previously done, vaccination administered no later than one week after the first drug administration
Women of childbearing potential: agreement to remain abstinent or use contraception during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final dose of eculizumab (or longer if required by the local product label)

Criterios de exclusión

Current or previous treatment with a complement inhibitor
History of allogeneic bone marrow transplantation
History of Neisseria meningitidis infection within 6 months prior to screening and up to first study drug administration
History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high
Pregnant or breastfeeding, or intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label)
Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater
Concurrent disease, treatment, procedure or surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the Investigator, preclude the participant's safe participation in and completion of the study
Splenectomy \< 6 months before screening
Positive for Active Hepatitis B and C infection (HBV/HCV)
History of or ongoing cryoglobulinemia at screening

Intervenciones

drug

Crovalimab

Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.

drug

Eculizumab

Eculizumab will be administered as specified in the respective arm.

Estudio Multicéntrico de Fase III, Aleatorizado, Abierto, con Control Activo para Evaluar la Eficacia y Seguridad de crovalimab Versus eculizumab en Pacientes con Hemoglobinuria Paroxística Nocturna (HPN) No Tratados Previamente con Inhibidores del Complemento

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Crovalimab

Eculizumab

Ubicaciones

Organizacion Medica de Investigacion (OMI)

Patrocinadores